Aspen Grove Capital’s Idexx Laboratories IDXX Stock Holding History

Aspen Grove Capital’s Portfolio IDXX Stock Details IDXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1,155	Closed	-$485K	–	250
2025 Q1	$485K	Buy	+1,155	New	+$502K	0.09%	116
2023 Q3	–	Sell	-1,807	Closed	-$908K	–	191
2023 Q2	$908K	Sell	1,807 -13	-0.7%	-$6.23K	0.29%	68
2023 Q1	$910K	Sell	1,820 -203	-10%	-$97.1K	0.4%	54
2022 Q4	$825K	Buy	+2,023	New	+$785K	0.38%	58

Other funds holding IDXX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Polen Capital Management Boca Raton, Florida $14.5B AUM 5.7% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Aspen Grove Capital's IDXX Position: Q2 2025 in Review

Aspen Grove Capital sold out of Idexx Laboratories (IDXX) in Q2 2025, closing a stake of 1,155 shares — an estimated $485K sold.

Aspen Grove Capital first reported a position in IDXX in Q4 2022 and held it in 4 quarters. The position peaked at $910K in Q1 2023. 1,234 funds tracked by Wall St. Rank hold IDXX as of Q2 2025.

Aspen Grove Capital reported no remaining Idexx Laboratories position as of Q2 2025 after selling out during the quarter.
Aspen Grove Capital sold 1,155 Idexx Laboratories shares in Q2 2025, an estimated $485K.
Aspen Grove Capital first reported a position in Idexx Laboratories in Q4 2022 and held it in 4 quarters.
Aspen Grove Capital's Idexx Laboratories position peaked at $910K in Q1 2023.
1,234 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2025.

Based on Aspen Grove Capital's 13F filing for Q2 2025, filed 14 Aug 2025.